Inpart

📊 New R&D Trends Report 🧬Our latest report maps the biotech landscape, focusing on early-stage assets and emerging platform technologies. What’s inside?    📌 A landscape of 30,000+ assets & discovery platforms  📌 Industry search campaign trends  📌 Pharma sentiment on biotech innovation  📌 A ranking of the most engaged assets, from biotechs including Avanti Research, Biotts, Engain (Environmental Gain Ltd), SCOHIA PHARMA, Inc., Evariste, Ainnocence, Oblique Therapeutics AB (publ.) and others Key findings include:  🔹 42% of clinical-stage biotech assets being small molecules addressing 1,000+ indications  🔹 AI-driven discovery, cell & gene therapies, and synthetic biology shaping the future of biotech R&D  🔹 Pharma R&D teams prioritizing clinically validated approaches with a clear path to market Download your copy here: https://lnkd.in/eVYXgHWS  #Biotech #Biopharma #LifeSciences #ResearchTrends #OpenInnovation 

AUTM 2025 is fast approaching 🏃🏻♀️➡️🤝 As our attendees begin to fill their meeting schedules (and yes, finally their suitcases too), we’re looking forward to connecting with technology transfer teams, industry partners, and researchers in Maryland. Whether you're exploring new ways to engage with industry, streamline your partnership workflows, or maximize the impact of your research, we’d love to chat! 📅 If you're attending, let’s set up a time to meet. Book in through the link below or stop by the Inpart booth. See you there! https://lnkd.in/eUrkX9fC #AUTM50 #AUTM2025 #TechTransfer

🔎 Our Connect campaign with Nippon Kayaku seeks research partners developing organic electro-optic polymer materials towards ultra high-speed and energy-saving optical communication technology. There is also interest in materials associated with Photonic assemblies and protective coatings. Read more about their campaign and requirements: https://lnkd.in/epGQH3KF #techtransfer #openinnovation #opticalcommunication

🚀 Looking to navigate biopharma partnerships? Our Partnering 2030 report shares insights from hundreds of biotechs, out-licensors, and research institutes - helping you connect with top pharma and VC investors. 📥 Get your copy now: https://lnkd.in/e_9crTFT  #biopharma #partnering #innovation

⏰ Closing soon! There’s still time to respond to our Connect campaign with Novo Nordisk. Their Transformational Prevention Unit (TPU) seeks partners in academia and biotech to develop innovative solutions that can prevent obesity and its consequences. Specifically, they are interested in science-backed opportunities to advance biological interventions. Make your submissions by 10th March: https://lnkd.in/eK6wdyb3 #techtransfer #openinnovation #obesity #prevention

📊 New R&D Trends Report 🧬Our latest report maps the biotech landscape, focusing on early-stage assets and emerging platform technologies. What’s inside?    📌 A landscape of 30,000+ assets & discovery platforms  📌 Industry search campaign trends  📌 Pharma sentiment on biotech innovation  📌 A ranking of the most engaged assets, from biotechs including Avanti Research, Biotts, Engain (Environmental Gain Ltd), SCOHIA PHARMA, Inc., Evariste, Ainnocence, Oblique Therapeutics AB (publ.) and others Key findings include:  🔹 42% of clinical-stage biotech assets being small molecules addressing 1,000+ indications  🔹 AI-driven discovery, cell & gene therapies, and synthetic biology shaping the future of biotech R&D  🔹 Pharma R&D teams prioritizing clinically validated approaches with a clear path to market Download your copy here: https://lnkd.in/eVYXgHWS  #Biotech #Biopharma #LifeSciences #ResearchTrends #OpenInnovation 

Want to see something RealCooL? ❄️🔥 ‘RealCooL’, developed by scientists at The University of Texas at Austin heats or cools liquids faster, safer, and more precisely than traditional methods. Compact, cost-effective, and self-sanitizing, their device can warm 240ml of milk from fridge to feeding temperature without hotspots in just 24 seconds for the little ones and chill a bottle of wine in under a minute for the adults! View the full tech overview on Inpart Connect 👉 https://lnkd.in/e9kEX2Wd #TechInnovation #OpenInnovation

🧐 Due diligence is a critical process that your team can't afford to get wrong. According to Mike Myers, Associate VP – Lilly Research Labs, Due Diligence at Eli Lilly and Company, effective due diligence requires the right subject matter experts, robust processes, and proper data and knowledge management. Fortify your due diligence process with Inpart Deal. Leverage best practices to empower due diligence managers, business development leads, and functional area experts, fostering seamless collaboration. Gain invaluable insights from #pharma leaders in our eBook:  https://lnkd.in/enQw8mYQ   

Our team might not be packed yet… but they’ve started gearing up for AUTM 2025 in Washington, D.C.! While the debate of ‘how many pairs of shoes is too many for a conference?’ rages on, our attending experts are at least sure of how to show you how we help tech transfer teams to turn research into real-world impact. 📅 Meet our team at AUTM 2025, to review how we’re helping universities and TTOs connect with the right industry partners to maximize the potential of their research (as well as the benefits of using packing cubes). Schedule a meeting now through this link: https://lnkd.in/ehfqYweT #AUTM2025 #TechTransfer

👋 Welcoming: Universidad Adolfo Ibáñez Coming all the way from Santiago, Chile, we say Bienvenidos to Universidad Adolfo Ibáñez as they begin showcasing their researchers’ early-stage innovations on Inpart Connect. 🌱 Their portfolio showcased on Connect is destined to have significant societal impact, with technologies spanning water harvesting and wastewater treatment, materials, agriculture, and renewable energy. Take a look here: https://lnkd.in/eqHDxD43 #techtransfer #researchinnovation #openinnovation